RT Journal Article
SR Electronic
T1 Characterising the persistence of RT-PCR positivity and incidence in a community survey of SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.12.21261987
DO 10.1101/2021.08.12.21261987
A1 Eales, Oliver
A1 Walters, Caroline E.
A1 Wang, Haowei
A1 Haw, David
A1 Ainslie, Kylie E. C.
A1 Atchison, Christina
A1 Page, Andrew J.
A1 Prosolek, Sophie J.
A1 Trotter, Alexander J.
A1 Le Viet, Thanh
A1 Alikhan, Nabil-Fareed
A1 Jackson, Leigh M
A1 Ludden, Catherine
A1 ,
A1 Ashby, Deborah
A1 Donnelly, Christl A.
A1 Cooke, Graham
A1 Barclay, Wendy
A1 Ward, Helen
A1 Darzi, Ara
A1 Elliott, Paul
A1 Riley, Steven
YR 2021
UL http://medrxiv.org/content/early/2021/08/13/2021.08.12.21261987.abstract
AB Background Community surveys of SARS-CoV-2 RT-PCR swab-positivity provide prevalence estimates largely unaffected by biases from who presents for routine case testing. The REal-time Assessment of Community Transmission-1 (REACT-1) has estimated swab-positivity approximately monthly since May 2020 in England from RT-PCR testing of self-administered throat and nose swabs in random non-overlapping cross-sectional community samples. Estimating infection incidence from swab-positivity requires an understanding of the persistence of RT-PCR swab positivity in the community.Methods During round 8 of REACT-1 from 6 January to 22 January 2021, of the 2,282 participants who tested RT-PCR positive, we recruited 896 (39%) from whom we collected up to two additional swabs for RT-PCR approximately 6 and 9 days after the initial swab. We estimated sensitivity and duration of positivity using an exponential model of positivity decay, for all participants and for subsets by initial N-gene cycle threshold (Ct) value, symptom status, lineage and age. Estimates of infection incidence were obtained for the entire duration of the REACT-1 study using P-splines.Results We estimated the overall sensitivity of REACT-1 to detect virus on a single swab as 0.79 (0.77, 0.81) and median duration of positivity following a positive test as 9.7 (8.9, 10.6) days. We found greater median duration of positivity where there was a low N-gene Ct value, in those exhibiting symptoms, or for infection with the Alpha variant. The estimated proportion of positive individuals detected on first swab, P0, was found to be higher for those with an initially low N-gene Ct value and those who were pre-symptomatic. When compared to swab-positivity, estimates of infection incidence over the duration of REACT-1 included sharper features with evident transient increases around the time of key changes in social distancing measures.Discussion Home self-swabbing for RT-PCR based on a single swab, as implemented in REACT-1, has high overall sensitivity. However, participants’ time-since-infection, symptom status and viral lineage affect the probability of detection and the duration of positivity. These results validate previous efforts to estimate incidence of SARS-CoV-2 from swab-positivity data, and provide a reliable means to obtain community infection estimates to inform policy response.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by the Department of Health and Social Care in England.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We obtained research ethics approval from the South Central-Berkshire B Research Ethics Committee (IRAS ID: 283787). The COG-UK study protocol was approved by the Public Health England Research Ethics Governance Group (reference: R&D NR0195). This study was conducted as part of surveillance for COVID-19 infections under the auspices of Section 251 of the NHS Act 2006 and/or Regulation 3 of The Health Service (Control of Patient Information) Regulations 2002. The REACT-1 study received research ethics approval from the South Central-Berkshire BResearch Ethics Committee (IRAS ID: 283787).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThese individual-level data are not yet available.